A Bayesian phase I–II clinical trial design to find the biological optimal dose on drug combination
Author:
Affiliation:
1. Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P.R. China
Funder
National Natural ScienceFoundation of China
Key R & D Program of Jiangsu Province
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,Statistics and Probability
Link
https://www.tandfonline.com/doi/pdf/10.1080/10543406.2023.2236208
Reference22 articles.
1. A Bayesian dose finding design for oncology clinical trials of combinational biological agents
2. Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
3. A weakly informative default prior distribution for logistic and other regression models
4. TEAMS: Toxicity- and Efficacy-Based Dose-Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology
5. Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3